Chai Discovery Raises $400M Series C at a $3.8B Valuation

Chai Discovery announced $400M in Series C financing on July 14, 2026. Chai Discovery raised a $400 million Series C led by Index Ventures to expand AI models for molecular design and pre-clinical drug discovery.

Round details

The financing includes backing from Index Ventures, Kleiner Perkins, Sequoia Capital. The company reported a $3.8B valuation alongside the transaction.

Round: Series C
Capital announced: $400M
Total funding reported: $600M+
Headquarters: San Francisco, CA

How the company plans to use the capital

Chai is expanding model development and commercial work around predicting and designing molecular interactions for pharmaceutical research.

Why this matters for GTM teams

The transaction is another signal that AI-native drug discovery companies are attracting platform-scale capital before traditional clinical-stage timelines.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Chai Discovery company announcement.